Evaluation of cell-killing effects of 1-β-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2629-2634

  Kishi, Shinji ^a   Goto, Nobuyuki ^a   Nakamura, Toru ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DAUNORUBICIN;

AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CELL STRAIN K 562; COMPUTER SIMULATION; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG EFFECT; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL DIVISION; CELL SURVIVAL; CISPLATIN; COMPUTER SIMULATION; CYTARABINE; DAUNORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; K562 CELLS; MODELS, CHEMICAL;

EID: 0033152213     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Balis, F. M., Holcenberg, J. S., and Bleyer, W. A. Clinical pharmacokinetics of commonly used anticancer drugs. Clin. Pharmacokinet., 8: 202-232, 1983.
2. Greenblatt, D. J., and Koch, W. I. Clinical pharmacokinetics. N. Engl J. Med., 293: 702-705, 1975.
3. Gale, R. P. Advances in the treatment of acute myelogenous leukemia. N. Engl. J. Med., 300: 1189-1199, 1979.
4. Nakamura, T., and Ueda, T. Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of 1-β-D-arabinofuranosylcytosine (ara-C) and its derivatives (in Japanese with English summary). Gan To Kagaku Ryoho, 9: 1339-1351, 1982.
5. Young, R. C., Ozols, R. F., and Myers, C. E. The anthracycline antineoplastic drugs. N. Engl. J. Med., 305: 139-153, 1981.
6. Paul, C., Liliemark, J., Tidefelt, U., Gahrton, G., and Peterson, C. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther. Drug Monit. 11: 140-148, 1989.
7. Alberts, D. S., Bachur, N. R., and Holtzman, J. L. The pharmacokinetics of daunomycin in man. Clin. Pharmacol. Ther., 12: 96-104, 1971.
8. Nishimura, M., Kumamoto, Y., Shibuya, A., Hirose, T., Tsukamoto, T., and Ohya, S. An in vitro study on the treatment of complicated cystitis using an automatic simulator (in Japanese with English summary). Kansenshogaku Zasshi, 64: 1004-1012, 1990.
9. Ueda, T., Kamiya, K., and Nakamura, T. The Pharmacokinetics and metabolism in leukemic cell of ara-C and its metabolites (in Japanese). Jpn. J. Clin. Pharmacol. Ther., 23: 365-369, 1992.
10. Ogawa, K., Matsuzaki, M., Miyashita, Y., Kimura, S., Ito, A., Okubo, T., Maruta, I., and Kodama, H. Pharmacokinetics of daunorubicin in leukemic patient (in Japanese). Chemotherapy, 35: 398-409, 1987.
11. Yamaoka, K., Nakagawa, T., Tanaka, H., Yasuhara, M., Okumura, K., and Hori, R. A nonlinear multiple regression program, MULTI2 (BAYES), based on Bayesian algorithm for microcomputers. J. Pharmacobiodyn., 8: 246-256, 1985.
12. Gimmel, S., and Maurer, H. R. Growth kinetics of L1210 leukemic cells exposed to different concentration courses of methotrexate in vitro. Cancer Chemother. Pharmacol., 34: 351-355, 1994.
13. Tatsumi, K., Nakamura, T., and Wakisaka, G. Comparative effect of daunomycin and Adriamycin on nucleic acid metabolism in leukemic cells in vitro. Gann, 65: 237-247, 1974.
14. Ozawa, S., Sugiyama, Y., Mitsuhashi, J., and Inaba, M. Kinetic analysis of cell killing effect induced by 1-β-D-arabinofuranosylcytosine and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res., 49: 3823-3828, 1989.
15. Rashbaum, S. A., and Cozzarelli, N. R. Mechanism of DNA synthesis inhibition by 1-β-D-arabinofuranoxylcytosine and arabinosyl adenine. Nature (Lond.), 264: 679-680, 1976.
16. Kufe, D. W., Major, P. P., Egan, E. M., and Beardsley, G. P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem., 255: 8997-9000, 1980.
17. Skipper, H. E., Schabel, F. J., Mellett, L. B., Montgomery, J. A., Wilkoff, L. J., Lloyd, H. H., and Brockman, R. W. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep., 54: 431-450, 1970.
18. Pigram, W. J., Fuller, W., and Hamilton, L. D. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nat. New Biol., 235: 17-19, 1972.
19. Painter, R. B. Inhibition of DNA replicon initiation by 4-nitroquinoline 1-oxide, Adriamycin, and ethyleneimine. Cancer Res., 38: 4445-4449, 1978.
20. Ross, W. E. DNA topoisomerases as targets for cancer therapy. Biochem. Pharmacol., 34: 4191-4195, 1985.
21. Deffie, A. M., Batra, J. K., and Goldenberg, G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res., 49: 58-62, 1989.
22. Ozawa, S., Sugiyama, Y., Mitsuhashi, Y., Kobayashi, T., and Inaba, M. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother. Pharmacol., 21: 185-190, 1988.
23. Andersson, B., Beran, M., Peterson, C., and Tribukait, B. Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin. Cancer Res., 42: 178-183, 1982.
24. Nguyen, N. T., Vrignaud, P., and Robert, J. Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors. Oncology, 41: 55-60, 1984.
25. Urasaki, Y., Ueda, T., Yoshida, A., Fukushima, T., Takeuchi, N., Tsuruo, T., and Nakamura, T. Establishment of a daunorubicin-resistant cell line which shows multidrug resistance by multifactorial mechanisms. Anticancer Res., 16: 709-714, 1996.
26. Legha, S. S., Benjamin, R. S., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S. L., Blumenschein, G. R., and Freireich, E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med., 96: 133-139, 1982.
27. Lewis, J. P., Meyers, F. J., and Tanaka, L. Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemia. Br. J. Haematol., 61: 261-265, 1985.
28. Paul, C., Tidefelt, U., Liliemark, J., and Peterson, C. Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time. Leuk. Res., 13: 191-196, 1989.
29. Hortobagyi, G. N., Frye, D., Buzdar, A. U., Ewer, M. S., Fraschini, G., Hug, V., Ames, F., Montague, E., Carrasco, C. H., Mackay, B., and Benjamin, R. S. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer (Phila.), 63: 37-45, 1989.
30. Barlogie, B., Smith, L., and Alexanian, R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med., 310: 1353-1356, 1984.
31. Alexanian, R., Barlogie, B., and Dixon, D. High-dose glucocorticoid treatment of resistant myeloma. Ann. Intern. Med., 105: 8-11, 1986.
32. Alexanian, R., Dimopoulos, M. A., Delasalle, K., and Barlogie, B. Primary dexamethasone treatment of multiple myeloma. Blood, 80: 887-890, 1992.
33. Muller, C., Chatelut, E., Gualano, V., De, F. M., Huguet, F., Altal, M., Canal, P., and Laurent, G. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother. Pharmacol., 32: 379-384, 1993.
34. Pieters, R., Loonen, A. H., Huismans, D. R., Broekema, G. J., Dirven, M. W., Heyenbrok, M. W., Hahlen, K., and Veerman, A. J. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood, 76: 2327-2336, 1990.
35. Demant, E. J., and Friche, E. Kinetics of anthracycline accumulation in multidrug-resistant tumor cells: relationship to drug lipophilicity and serum albumin binding. Biochem. Pharmacol., 56: 1209-1217, 1998.
36. Mi, Z., Malak, H., and Burke, T. G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry, 34: 13722-13728, 1995.